Redesigning Canada’s health policy to spur innovation

When patents create an unbalanced system of protection, regulatory exclusivities, which safeguard a firm’s data from being copied by competitors while still allowing scientific collaboration, offer a better alternative.

If Canada is to address rare and complex diseases, we need to encourage firms to explore exclusivities that genuinely drive innovation, writes E. Richard Gold.Photograph courtesy of the National Cancer Institute via Unsplash

Opinion

BY E. RICHARD GOLD

December 22, 2025

The next health crisis is coming, and Canada is unprepared. COVID-19 cost this country's economy

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy